As part of our ongoing development / improvement of our bioanalytical capabilities, ABF has purchased a new GC-MS/MS system:

Shimadzu GCMS-TQ8050

The improved specificity allowed us to optimize our method for the analysis of hemoglobin-adducts such as cyanothylvalin,

a potential clinical biomarker of compliance for use in next-generation tobacco product switching studies (e.g. heat-not-burn, e-cigarettes)